Format

Send to

Choose Destination
Internist (Berl). 2016 Feb;57(2):136-41. doi: 10.1007/s00108-015-0011-9.

[New drugs for treatment of tuberculosis].

[Article in German]

Author information

1
Zentrum für Pneumologie, Agaplesion Diakonieklinikum Rotenburg, Elise-Averdieck-Str. 17, 27356, Rotenburg, Deutschland. schaberg@diako-online.de.

Abstract

New effective drugs for the treatment of tuberculosis (TB) are necessary for two main reasons: firstly, it would be desirable to reduce the duration of TB treatment from 6 to 4 months and secondly, new drugs are urgently needed for the treatment of multidrug-resistant strains of Mycobacterium tuberculosis. For the first time since 1960 the two new drugs bedaquiline and delamanid were approved and licensed in 2014 for the treatment of multidrug-resistant M. tuberculosis; however, efforts to reduce the duration of treatment to 4 months using fluoroquinolones have not been successful. Further new drugs are currently in phase 2 and phase 3 studies; therefore, new treatment options can be expected within the next few years.

KEYWORDS:

Bedaquiline; Delamanid; Fluoroquinolones; PA-824; Tuberculosis, multidrug resistant

PMID:
26787496
DOI:
10.1007/s00108-015-0011-9
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center